Loading...
Docoh
Log in Free sign up

Acura Pharmaceuticals (ACUR)

Acura Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the research, development, and commercialization of abuse deterrent, orally administered pharmaceutical products. Its technology platforms include AVERSION, IMPEDE, and LIMITX. The company was founded on April 10, 1935 and is headquartered in Palatine, IL.

Company profile

Ticker
ACUR
Exchange
NASDAQ
Website
acurapharm.com/
CEO
Robert Jones
Employees
Incorporated
New York
Location
Illinois
Fiscal year end
Dec 31
Sector
Manufacturing > Pharmaceutical Preparation Manufacturing
Industry (SIC)
Pharmaceutical Preparations
Pfizer • Johnson & Johnson • Merck & Co • Allergan • Abbott Laboratories • Teva- Pharmaceutical Industries • Lilly(Eli) & Co • Bristol-Myers Squibb • Viatris • Abbvie ...
Former names
HALSEY DRUG CO INC/NEW
SEC CIK
0000786947
Corporate docs
IRS number
110853640

ACUR stock data

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

16 May 22
12 Aug 22
31 Dec 22

Financial summary

Financial statements Chart ACUR financial data
Quarter (USD) Sep 21 Jun 21 Mar 21 Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 89K 89K 89K 89K 89K 89K
Cash burn (monthly) 26K 33.67K 177K 118.33K (no burn) 33K
Cash used (since last report) 271.65K 351.75K 1.85M 1.24M n/a 344.78K
Cash remaining -182.65K -262.75K -1.76M -1.15M n/a -255.78K
Runway (months of cash) -7.0 -7.8 -9.9 -9.7 n/a -7.8

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Recent insider trades

ACUR insider ownership history Insider history
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
3 Aug 22 Peter A Clemens Common Stock Option exercise Acquire M No No 0 49,333 0 465,430
3 Aug 22 Peter A Clemens RSU Common Stock Option exercise Acquire M No No 0.01 40,000 400 80,000
3 Aug 22 Peter A Clemens RSU Common Stock Option exercise Acquire M No No 0.01 9,333 93.33 120,000
3 Aug 22 Robert B Jones Common Stock Option exercise Acquire M No No 0 63,666 0 553,555
3 Aug 22 Robert B Jones RSU Common Stock Option exercise Acquire M No No 0.01 50,000 500 90,000
3 Aug 22 Robert B Jones RSU Common Stock Option exercise Acquire M No No 0.01 13,666 136.66 140,000
3 Aug 22 Robert A Seiser Common Stock Option exercise Acquire M No No 0 24,666 0 378,254
3 Aug 22 Robert A Seiser RSU Common Stock Option exercise Acquire M No No 0.01 20,000 200 60,000
3 Aug 22 Robert A Seiser RSU Common Stock Option exercise Acquire M No No 0.01 4,666 46.66 80,000
3 Aug 22 Albert W Brzeczko Common Stock Option exercise Acquire M No No 0 43,333 0 412,001
Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Institutional ownership, Q4 2021

ACUR institutional ownership history Ownership history
81.0% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 2 2 –
Opened positions 0 0
Closed positions 0 1 EXIT
Increased positions 0 0
Reduced positions 0 0
13F shares Current Prev Q Change
Total value 21.49M 21.49M –
Total shares 52.99M 52.99M –
Total puts 0 0
Total calls 0 0
Total put/call ratio – – –
Largest owners Shares Value Change
Schutte John 52.98M $21.49M 0.0%
Lenox Wealth Advisors 780 $0 0.0%
Largest transactions Shares Bought/sold Change
Lenox Wealth Advisors 780 0 0.0%
Schutte John 52.98M 0 0.0%
Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Financial report summary

?
Competition
Pfizer • Nektar Therapeutics • Elite Pharmaceuticals • Cassava Sciences • Acelrx Pharmaceuticals • KemPharm • Perrigo

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: Letter, physiologic, Sep, stringent
Removed: accruing, beginning, commitment, disbursement, epidemiology, granting
From filing 10-Q 2021 Q3
Financial reports
View all
NT 10-Q
Notice of late quarterly filing
16 May 22
NT 10-K
Notice of late annual filing
31 Mar 22
10-Q
2021 Q3
Quarterly report
14 Nov 21
10-Q
2021 Q2
Quarterly report
16 Aug 21
10-Q
2021 Q1
Quarterly report
17 May 21
10-K
2020 FY
Annual report
31 Mar 21
10-Q
2020 Q3
Quarterly report
16 Nov 20
10-Q
2020 Q2
Quarterly report
14 Aug 20
10-Q
2020 Q1
Quarterly report
28 Jun 20
10-K
2019 FY
Annual report
30 Mar 20
Current reports
View all
8-K
Other Events
28 Jul 22
8-K
Entry into a Material Definitive Agreement
19 Jul 22
8-K
Other Events
14 Jul 22
8-K
Entry into a Material Definitive Agreement
11 Jul 22
8-K
Entry into a Material Definitive Agreement
13 Jun 22
8-K
Entry into a Material Definitive Agreement
23 May 22
8-K
Other Events
19 May 22
8-K
Entry into a Material Definitive Agreement
2 May 22
8-K
Entry into a Material Definitive Agreement
4 Apr 22
8-K
Entry into a Material Definitive Agreement
1 Mar 22
Registration and prospectus
View all
S-8
Registration of securities for employees
1 Jun 21
RW
Registration withdrawal request
31 Jul 18
S-8
Registration of securities for employees
16 Nov 17
D
$4M in equity / options / securities to be acquired, sold $4M, 1 investor
27 Jul 17
25-NSE
Exchange delisting
13 Mar 17
S-1
IPO registration
2 Feb 17
S-8
Registration of securities for employees
8 Aug 16
S-3/A
Shelf registration (amended)
22 Mar 16
S-3
Shelf registration
8 Mar 16
424B5
Prospectus supplement for primary offering
30 Jun 15
Proxies
View all
DEF 14A
Definitive proxy
12 Apr 21
DEF 14A
Definitive proxy
26 Sep 17
DEFA14A
Additional proxy soliciting materials
26 Sep 17
DEFA14A
Additional proxy soliciting materials
12 Apr 16
DEF 14A
Definitive proxy
6 Mar 16
DEFA14A
Additional proxy soliciting materials
6 Mar 16
DEFA14A
Additional proxy soliciting materials
20 Jul 15
DEF 14A
Definitive proxy
13 Jul 15
PRE 14A
Preliminary proxy
21 Jun 15
DEF 14A
Definitive proxy
17 Mar 15
Other
View all
CT ORDER
Confidential treatment order
9 Apr 18
CT ORDER
Confidential treatment order
14 Jun 17
EFFECT
Notice of effectiveness
29 Mar 16
CORRESP
Correspondence with SEC
24 Mar 16
UPLOAD
Letter from SEC
17 Mar 16
CT ORDER
Confidential treatment order
23 Feb 16
CT ORDER
Confidential treatment order
4 May 15
UPLOAD
Letter from SEC
16 Oct 14
CORRESP
Correspondence with SEC
14 Oct 14
CORRESP
Correspondence with SEC
28 Sep 14
Ownership
View all
4
ACURA PHARMACEUTICALS / Albert W Brzeczko ownership change
5 Aug 22
4
ACURA PHARMACEUTICALS / Robert B Jones ownership change
5 Aug 22
4
ACURA PHARMACEUTICALS / Robert A Seiser ownership change
5 Aug 22
4
ACURA PHARMACEUTICALS / PETER A CLEMENS ownership change
5 Aug 22
4
ACURA PHARMACEUTICALS / Robert A Seiser ownership change
18 Mar 22
4
ACURA PHARMACEUTICALS / Robert B Jones ownership change
18 Mar 22
4
ACURA PHARMACEUTICALS / PETER A CLEMENS ownership change
18 Mar 22
4
ACURA PHARMACEUTICALS / Albert W Brzeczko ownership change
18 Mar 22
SC 13D/A
ACURA PHARMACEUTICALS / ESSEX WOODLANDS HEALTH VENTURES FUND V ownership change
14 Feb 22
4
ACURA PHARMACEUTICALS / IMMANUEL THANGARAJ ownership change
12 Jan 22

Patents

View all
Utility
Methods and Compositions for Interfering with Extraction or Conversion of a Drug Susceptible to Abuse
3 Mar 22
Effective methods and compositions to deter abuse of pharmaceutical products (e.g., orally administered pharmaceutical products) including but not limited to immediate release, sustained or extended release and delayed release formulations for drugs subject to abuse.
Utility
Methods and compositions for interfering with extraction or conversion of a drug susceptible to abuse
14 Dec 21
Effective methods and compositions to deter abuse of pharmaceutical products (e.g., orally administered pharmaceutical products) including but not limited to immediate release, sustained or extended release and delayed release formulations for drugs subject to abuse.
Utility
Methods and Compositions for Self-regulated Release of Active Pharmaceutical Ingredient
28 Oct 21
An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.
Utility
Methods and compositions for self-regulated release of active pharmaceutical ingredient
31 Aug 21
An abuse deterrent pharmaceutical composition including an acid soluble salt of a pharmaceutically active ingredient and a buffering ingredient; wherein the acid soluble salt of the pharmaceutically active ingredient and the buffering ingredient retard release of the pharmaceutically active ingredient when the composition is ingested in excess of an intended dosage.
Utility
Methods and compositions for self-regulated release of active pharmaceutical ingredient
10 Aug 21
An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.